💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

UPDATE 2-Glaxo buys protein-drinks firm Maxinutrition

Published 12/13/2010, 07:34 AM
Updated 12/13/2010, 07:36 AM

* Glaxo buys firm for 162 million pounds cash

* Protein products complement Lucozade, Horlicks franchises

* Glaxo CEO sees new opportunities from broadening business

(Adds comments from Glaxo CEO)

By Paul Sandle

LONDON, Dec 13 (Reuters) - GlaxoSmithKline is buying protein drinks firm Maxinutrition for 162 million pounds ($256 million) from its private-equity owners to complement its Lucozade sports drinks and Horlicks franchises.

Glaxo Chief Executive Andrew Witty said the deal, which is priced at 4.5 times last year's sales, would give the drugmaker a broad range of nutritional drink products as it seeks to build up its consumer healthcare business.

"It fits beautifully with the Lucozade business," Witty told Reuters in an interview.

"The more subtle part is that if you think about GSK now, we have a carbohydrates nutrition business with Lucozade, we have a calcium micronutrients business which is Horlicks, and now we have a protein nutritional business."

Glaxo said on Monday it was buying the company from Darwin Private Equity for 162 million pounds in cash, including the repayment of outstanding debt.

British-based Maxinutrition is Europe's leading sports nutrition company by market share, with a line-up of products that includes Maximuscle for weight-trainers, as well as Maxifuel and Maxitone.

It recorded sales of about 36 million pounds in the year to end-April 2010 and has delivered annual sales growth of approximately 21 percent over the last 3 years.

Witty said the broad base in three different types of nutritional healthcare products could allow Glaxo to contemplate a range of innovations in future.

"You could then imagine a whole series of new products at all levels of the system -- you could imagine elite sports products, you could imagine nutrition for the elderly, and you could also imagine daily nutritional supplements for people in Africa," he said.

The deal is subject to approval from Britain's Office of Fair Trading. (Additional reporting by Ben Hirschler and Kate Kelland; Editing by Hans Peters) ($1=.6335 Pound)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.